Itraconazole

Major

Itraconazole Dronabinol Marinol Increased cannabinoid exposure and an increased risk of cannabinoid-related adverse effects Details Itraconazole Dutasteride Avodart Increased dutasteride exposure and an increased risk of dutasteride-related adverse effects Details Itraconazole Edoxaban Savaysa Increased edoxaban exposure Details Itraconazole Elacestrant Orserdu Increased elacestrant exposure and an increased risk of elacestrant-related adverse effects Details Itraconazole Enasidenib Idhifa Reduced antifungal exposure and reduced efficacy of antifungal agent Details Itraconazole Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse reactions and an increased risk of QT interval pr... Details Itraconazole Entrectinib Rozlytrek Increased entrectinib exposure, increased frequency or severity of adverse reactions including increased risk of cardiac arrhythmi... Details Itraconazole Eravacycline Injection Xerava Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Erdafitinib Balversa Increased erdafitinib exposure Details Itraconazole Eribulin Injection Halaven An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Erlotinib Tarceva Increased erlotinib exposure and risk of toxicity Details Itraconazole Estradiol Delestrogen Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Estradiol Topical Divigel Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Estradiol Transdermal Patch Alora® Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Everolimus Afinitor Increased everolimus exposure Details Itraconazole Famotidine Calmicid Reduced itraconazole exposure and an increased risk of QT interval prolongation Details Itraconazole Famotidine Injection Calmicid Reduced itraconazole exposure and an increased risk of QT interval prolongation Details Itraconazole Felbamate Felbatol An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure, increased or prolonged opioid effects (CNS depression, respiratory depression) Details Itraconazole Fexofenadine Allegra Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse effects Details Itraconazole Flecainide Tambocor® An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Itraconazole Fostamatinib Tavalisse Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Fostemsavir Rukobia Increased fostemsavir exposure and an increased risk of QT interval prolongation Details Itraconazole Futibatinib Lytgobi Increased futibatinib exposure and increased risk of futibatinib-related adverse reactions Details Itraconazole Galantamine Razadyne Increased galantamine exposure and an increased risk of galantamine-related adverse effects Details Itraconazole Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Gefitinib Iressa Increased gefitinib exposure and an increased risk of gefitinib-related adverse effects Details Itraconazole Gemifloxacin Factive An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Gilteritinib Xospata Increased gilteritinib plasma concentrations Details Itraconazole Glasdegib Daurismo Increased glasdegib concentration and increased risk of QTc interval prolongation Details Itraconazole Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Itraconazole Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Granisetron Injection Granisol An increased risk of QT interval prolongation and torsade de pointes Details Itraconazole Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Itraconazole Hydrocortisone Ala-Cort Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Hydrocortisone Injection A-Hydrocort® Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse effects Details Itraconazole Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Itraconazole Ibrexafungerp Brexafemme Increased ibrexafungerp exposure Details Itraconazole Ibrutinib Imbruvica Increased ibrutinib exposure Details